Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments
-- Avid Revenue Guidance Increased to $60 - $65 Million for Full FY 2017 and Contracted Backlog of Future Business Currently at $70 Million -- -- Multiple Preclinical Studies Demonstrating Bavituximab’s Ability to Enhance Activity of Immune Stimulating …